Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT329 in Advanced Solid Tumors Expressing CA19-9
NCT07186842Phase 2Recruiting
- Sponsor
- BioNTech SE
- Start
- Nov 2025
- Primary completion
- May 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
A Phase 2 trial of BNT329 in solid tumor (advanced stage), pancreatic ductal adenocarcinoma (PDAC), cholangiocarcinoma (CCA), bladder cancer, colorectal cancer (CRC), sponsored by BioNTech SE. Started Nov 2025; status: recruiting.
02
Drugs
BNT329
03
Conditions
solid tumor (advanced stage)pancreatic ductal adenocarcinoma (PDAC)cholangiocarcinoma (CCA)bladder cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07186842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186842.